Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.42 |
| ▸ | FABP7 | O15540 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2583787 | 1.00 | EPHX2 (0.43) | EPHX2FABP5FABP7KMT2ACASP3 | |
| SCHEMBL30792927 | 1.00 | EPHX2 (0.43) | EPHX2FABP5FABP7KMT2ACASP3 | |
| SCHEMBL30896020 | 1.00 | EPHX2 (0.43) | EPHX2FABP5FABP7KMT2ACASP3 | |
| SCHEMBL30016334 | 1.00 | EPHX2 (0.43) | EPHX2FABP5FABP7KMT2ACASP3 | |
| SCHEMBL2583781 | 1.00 | EPHX2 (0.43) | EPHX2FABP5FABP7KMT2ACASP3 | |
| SCHEMBL30896027 | 1.00 | EPHX2 (0.43) | EPHX2FABP5FABP7KMT2ACASP3 | |
| SCHEMBL31742570 | 0.93 | EPHX2 (0.44) | EPHX2FABP5FABP7KMT2ACASP3 | |
| SCHEMBL28365887 | 0.85 | EPHX2 (0.46) | EPHX2FABP5FABP7KMT2ACASP3 | |
| SCHEMBL6532381 | 0.83 | CASP3 (0.43) | EPHX2KMT2ACASP3 | |
| SCHEMBL8120555 | 0.83 | EPHX2 (0.44) | EPHX2FABP5FABP7KMT2ACASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4512818-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | Chugai Seiyaku Kabushiki Kaisha (JP) | 2025-02-26 | — | — | EP | disclosed |
| US-20240158446-A1 | CYCLIC COMPOUND HAVING SELECTIVE INHIBITORY ACTION ON KRAS OVER HRAS AND NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-16 | — | — | US | disclosed |
| EP-4309741-A1 | CYCLIC COMPOUND HAVING INHIBITORY EFFECT SELECTIVE FOR KRAS BUT NOT FOR HRAS AND NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-01-24 | — | — | EP | disclosed |
| US-20180099937-A1 | NOVEL ARYL-CYANOGUANIDINE COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-04-12 | — | — | US | disclosed |
| EP-3283480-A1 | NOVEL ARYL-CYANOGUANIDINE COMPOUNDS | Bayer Pharma Aktiengesellschaft (DE) | 2018-02-21 | — | — | EP | disclosed |
| WO-2016166186-A1 | NOVEL ARYL-CYANOGUANIDINE COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158446-A1 | CYCLIC COMPOUND HAVING SELECTIVE INHIBITORY ACTION ON KRAS OVER HRAS AND NRAS | KRAS, HRAS, NRAS | EPHX2 3517/4885FABP5 4703/4885FABP7 4408/4885 |
| US-20180099937-A1 | NOVEL ARYL-CYANOGUANIDINE COMPOUNDS | SMYD2, SETD2, SMYD3 | EPHX2 3767/4885FABP5 3856/4885FABP7 4596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.